

DEVELOPMENTAL THERAPEUTICS SYMPOSIUM



AT THE FOREFRONT

UChicago Medicine

Comprehensive Cancer Center

The University of Chicago
Comprehensive Cancer Center
5841 S. Maryland Avenue
Chicago, IL 60637

Follow us on Twitter: @UChicagoCME

The goals of this activity are to help participants examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rationale for and results of studies that include novel agents for the treatment of patients with advanced cancer. This knowledge will enable them to appropriately utilize new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research. In sum, this program will convey information on how to better implement precision medicine in oncologic care, leading to better outcomes for patients suffering from cancer.



AT THE FOREFRONT

UChicago Medicine

Comprehensive Cancer Center



SCAN OR VISIT TO REGISTER TODAY!

www.UofCDevelopmentalTherapeuticsSymposium.org

QUESTIONS? Contact Meeting Achievements at
Leslie@meetingachievements.com Or 219.465.1115

ACCREDITED BY UNIVERSITY OF CHICAGO



27TH
UNIVERSITY
OF CHICAGO
COMPREHENSIVE
CANCER CENTER

DEVELOPMENTAL THERAPEUTICS SYMPOSIUM



AT THE FOREFRONT

UChicago Medicine

Comprehensive Cancer Center

MAY 10, 2024

JOIN US IN-PERSON!

**DAVID RUBENSTEIN FORUM
CHICAGO, ILLINOIS**

PROGRAM INFORMATION

TARGET AUDIENCE

This activity has been designed for physicians and other healthcare professionals currently involved in the diagnosis, screening, and treatment of cancer patients.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- State the clinical effects of novel immunotherapeutic agents, including but not limited to novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
- Describe the current science related to radioligand therapy and available agents;
- Discuss advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.
- Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.

ACCREDITATION AND CREDIT DESIGNATION STATEMENT

PHYSICIAN CREDIT: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **5.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT: University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn **5.25** contact hours.

AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **5.25** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OTHER HEALTH PROFESSIONAL CREDIT: Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

AGENDA: MAY 10, 2024

8:15 am	REGISTRATION/ BREAKFAST/EXHIBITS	12:20 pm	*CONCURRENT LUNCHTIME BREAKOUTS
8:45 am	WELCOME	1: For Internal Research Staff/Nurses	Moderator Lauren Wall
	SESSION 1	Regulatory and Pragmatic Issues for Running Cancer and Clinical Trials	Livia Szeto Sara Moelling Lauren Wall
Moderator	Walter Stadler, MD	2: For Physicians	Moderator Walter Stadler, MD
	The Current Landscape of Novel Therapeutics in Breast Cancer	Dose Optimization in Cancer Drug Development	Mark Ratain, MD
	Nan Chen, MD	1:05 pm	BREAK/EXHIBITS
	New Treatment Approaches for Lung Cancer	1:20 pm	SESSION 3
	Marina Garassino, MD	Moderator	Toyosi Odenike, MD
	New Frontiers: Novel therapeutic approaches in head and neck cancer		Advancing Solid Tumor Cell Therapy
	Ari Rosenberg, MD		Dan Olson, MD
10:05 am	BREAK/EXHIBITS		Novel Therapies in Gynecologic Malignancies
10:25 am	SESSION 2		Diane Yamada, MD
Moderator	Toyosi Odenike, MD		Novel Precision Therapeutics in GU Malignancies: Theranostics and Antibody Conjugates
	BCMA and Beyond: The Next Generation of Immunotherapies in Multiple Myeloma		Russ Szmulewitz, MD
	Benjamin Derman, MD	2:35 pm	CLOSING REMARKS
	Emerging Targets and Strategies in Hepatobiliary Cancers		Toyosi Odenike, MD Walter Stadler, MD
	Joseph Franses, MD, PhD	2:40 pm	ADJOURN
	Optimizing Cellular Therapy in Lymphoma	2:40 pm	POST-CONFERENCE RECEPTION
	Peter Riedell, MD		For Trainees (Residents & Fellows) Developing a Career in Clinical Research
	The Evolving Treatment Paradigm for Acute Leukemia and Myeloid Neoplasms		Walter Stadler, MD Toyosi Odenike, MD
	Anand Patel, MD		
12:05 pm	LUNCH/ LUNCHTIME BREAKOUTS		

COURSE DIRECTORS



Walter Stadler, MD
Fred C. Buffett Professor of Medicine
Dean for Clinical Research
Senior Advisor to
Comprehensive Cancer
Center Director
University of Chicago



Toyosi Odenike, MD
Professor of Medicine
Director,
Leukemia Program
University of Chicago



REGISTER TODAY!
SCAN or VISIT:

UofCDevelopmentalTherapeuticsSymposium.org

